Celsion to Present at Three Investment Conferences in October

Rhea-AI Summary

Celsion Corporation (NASDAQ: CLSN), a clinical-stage biotechnology company, announced its participation in several investment conferences in October 2021. Key events include a presentation at Chardan’s 5th Annual Genetic Medicines Conference on October 5, a virtual presentation at LD Micro Main Event on October 12, and participation in an oncology panel at Alliance Global Partners’ Virtual Healthcare Conference on October 13. Live and archived webcasts will be available online. Celsion focuses on DNA-based immunotherapy, with products like GEN-1 and ThermoDox® in its pipeline.

LAWRENCEVILLE, N.J., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management will present at the following investment conferences in October:

• Chardan’s 5^th Annual Genetic Medicines Conference. Michael H. Tardugno, Celsion’s chairman, president and chief executive officer, and Khursheed Anwer, Ph.D., Celsion’s chief scientific officer, will participate in a presentation and fireside chat on October 5, 2021 at 4:30 p.m. ET. Management will be available for 1x1 meetings on October 4 and 5, and investors should contact their Chardan representative to arrange a virtual meeting.
• LD Micro Main Event. Jeffrey W. Church, chief financial officer, will present virtually at 9:00 a.m. ET on October 12, 2021.
• Alliance Global Partners’ Virtual Healthcare Conference. Mr. Tardugno will participate in an oncology focused panel discussion moderated by James Molloy on October 13, 2021 at 9:00 a.m. ET.
  

Live and archived webcasts of these presentations will be available here.

About Celsion Corporation

Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox^®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. For more information on Celsion, visit www.celsion.com.

CONTACTS:

Celsion Corporation
Jeffrey W. Church
Executive Vice President and CFO
609-482-2455
jchurch@celsion.com

LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com

# # #

FAQ

When is Celsion Corporation presenting at the Chardan’s 5th Annual Genetic Medicines Conference?

Celsion Corporation will present at Chardan’s 5th Annual Genetic Medicines Conference on October 5, 2021, at 4:30 p.m. ET.

What time is Celsion's presentation at the LD Micro Main Event?

Celsion's presentation at the LD Micro Main Event is scheduled for October 12, 2021, at 9:00 a.m. ET.

Who will represent Celsion at the Alliance Global Partners’ Virtual Healthcare Conference?

Michael H. Tardugno will participate in an oncology panel discussion at the Alliance Global Partners’ Virtual Healthcare Conference on October 13, 2021, at 9:00 a.m. ET.

How can investors access Celsion's presentation webcasts?

Investors can access live and archived webcasts of Celsion's presentations through their official website.

What is the focus of Celsion Corporation's research?

Celsion Corporation focuses on DNA-based immunotherapy and next-generation vaccines, including products like GEN-1 for ovarian cancer.